Coronavirus Update: Moderna’s COVID-19 Vaccine Passes First Test In Elderly Patients
Encouraging Results From Phase I Study
Plus: Korea approves Celltrion antibody trial in mild patients, promising signs for Translate Bio's mRNA candidate in animal studies.
You may also be interested in...
CDC developing vaccine distribution plans with four states and one large city that will serve as a ‘foundation’ for other jurisdictions; plans include provisions for all potential vaccines, but logistics will vary depending on product, especially given the cold chain issues associated with mRNA vaccines from Pfizer and Moderna.
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.